Z
Zhihui Zhou
Researcher at Jiangxi Science and Technology Normal University
Publications - 8
Citations - 69
Zhihui Zhou is an academic researcher from Jiangxi Science and Technology Normal University. The author has contributed to research in topics: Apoptosis & Lead compound. The author has an hindex of 3, co-authored 8 publications receiving 17 citations.
Papers
More filters
Journal ArticleDOI
The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation
TL;DR: The recent advances in medicinal chemistry of fourth-generation EGFR-TKIs are discussed, as well as further discussed the clinical challenges and future prospects of treating patients with EGFR mutations resistant to third-generationEGFR- TKIs.
Journal ArticleDOI
Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations
Zhen Xiao,Zhihui Zhou,Cilong Chu,Qian Zhang,Lingjia Zhou,Zunhua Yang,Xin Li,Liying Yu,Pengwu Zheng,Shan Xu,Wufu Zhu +10 more
TL;DR: Five series of novel thiophene-pyrimidine derivatives synthesized and tested for their anti-proliferative activity against several cancer cell lines in which EGF is highly expressed showed excellent activity against one or more cancer cell Lines.
Journal ArticleDOI
Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors.
Zhen Xiao,Cilong Chu,Lingjia Zhou,Zhihui Zhou,Qian Zhang,Feiyi Yang,Zunhua Yang,Pengwu Zheng,Shan Xu,Wufu Zhu +9 more
TL;DR: Cell cycle and apoptosis analysis suggested that 13a could block cancer cells in G2/M phase and induce into late apoptosis in a manner of concentration-dependent, and structure-activity relationship of 13a was analyzed to explore its mechanism.
Journal ArticleDOI
Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors.
TL;DR: In this article, a class of 2-aryl-4-aminoquinazoline derivatives (7a-7j, 8a-8h, 9a-9h and 10a-10k) were designed, synthesized and evaluated as EGFR inhibitors.
Patent
Pyrimidine compound containing substituted phenyl acrylamide structure and application of compound
Zhu Wufu,Pengwu Zheng,Bingbing Zhao,Shan Xu,Zhen Xiao,Xiaohan Hu,Zhihui Zhou,Jie He,Lai Luogen,Qi Yang,Fajuan Tian +10 more
TL;DR: In this paper, a pyrimidine compound containing a substituted phenyl acrylamide structure, a geometric isomer of the compound, and pharmaceutically acceptable salts, hydrates, solvates or prodrugs is presented.